Trevi Therapeutics (TRVI) Operating Leases (2018 - 2026)

Trevi Therapeutics' Operating Leases history runs 9 years deep, the most recent figure standing at $364000.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 46.55% year-over-year to $364000.0; the TTM figure through Mar 2026 stood at $364000.0 (down 46.55% YoY), while the FY2025 annual figure was $446000.0, down 40.29% from the prior year.
• Operating Leases for Q1 2026 stood at $364000.0, down from $446000.0 in the prior quarter.
• The five-year high for Operating Leases was $1.1 million in Q1 2023, with the low at $2000.0 in Q3 2022.
• The 5-year median for Operating Leases is $714000.0 (2024), against an average of $645375.0.
• The sharpest annual moves came in 2022 and 2023: Operating Leases slumped 96.7% in 2022, then jumped 52450.0% in 2023.
• Trevi Therapeutics' Operating Leases stood at $2000.0 in 2022, then jumped by 49950.0% to $1.0 million in 2023, then decreased by 25.37% to $747000.0 in 2024, then tumbled by 40.29% to $446000.0 in 2025, then slipped by 18.39% to $364000.0 in 2026.
• Business Quant data shows TRVI's Operating Leases at $364000.0 in Q1 2026, $446000.0 in Q4 2025, and $527000.0 in Q3 2025.